Signal active
Organization
Contact Information
Overview
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. The company is focused on targeting common pathology in all systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options.
About
Biotechnology, Health Care, Medical, Biopharma
2019
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Attralus headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Biopharma sector. The company focuses on Biotechnology and has secured $9.5B in funding across 48 round(s). With a team of 11-50 employees, Attralus is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Attralus, raised $56.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
3
7
0
$197.0M
Details
3
Attralus has raised a total of $197.0M in funding over 3 rounds.
Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
---|---|---|---|---|
2020 | Early Stage Venture | 25.0M | ||
2021 | Early Stage Venture | 116.0M | ||
2024 | Early Stage Venture | 56.0M |
Investors
Attralus is funded by 27 investors.
Investor Name | Lead Investor | Funding Round | Partners |
---|---|---|---|
Sarissa Capital Management | - | FUNDING ROUND - Sarissa Capital Management | 56.0M |
Richard Gaster | - | FUNDING ROUND - Richard Gaster | 56.0M |
Attralus | - | FUNDING ROUND - Attralus | 56.0M |
venBio Partners | - | FUNDING ROUND - venBio Partners | 56.0M |
Recent Activity
There is no recent news or activity for this profile.